At Dennis Partners, we know regulatory recruiting. We are committed to creating and maintaining partnerships with our clients while upholding the highest standards of professionalism and ethics. Our team interacts within the marketplace on a daily basis, giving us the ability to locate, screen, and recommend exceptional individuals to your firm. We know how to identify the top performers. Our strength is partnering with you and your business to develop a solution and meet demands for growth while improving efficiency. Let our advanced expertise find the top professionals in the industry to provide a competitive edge to your company.
Industry Experience
We have your specialization covered
Thorough Methodoloy
Contract-to-hire evaluation process
We're on your side
Complete back office support
Outsourced
Our process is cost-effective
Testimonials
Dennis Partner’s focus on only regulatory affairs searches gives them a very good sense of the market, the available talent, and who matches the role. They worked with us diligently to find the right candidate and we ended up making an exceptional hire.
Our Process
Evaluate
We take the time to evaluate your needs beyond a job description
Identify
We identify top talent from our research and competitive analysis
Analyze
We analyze the talent to match candidates on a deeper level
Outcome
We go beyond the hire by offering extensive post placement services
Does your company have immediate top-tier talent needs?
Meet Our Team
Jilma Sweeney
Jack Vendetti
Jessie Alexander
Open Positions
What's New
Regulatory Landscape Newsletter – November 2019
This is our Regulatory Landscape newsletter for November 2019 with our insights on the evolving market for regulatory professionals. For the month of October, hiring in regulatory remained very strong. The ongoing trend continued with a high demand for senior clinical regulatory strategy and regulatory CMC professionals at the Director and Senior Director levels. Most[…]
SRA Update November/December 2019
Motivate and inspire. The two words are often used interchangeably, echoed perpetually in the minds of any leader trying to spearhead the charge. However, view the two as the same and you are missing a critical component in your evolution as a senior executive. Why? Motivation is of the ego, while inspiration is of the[…]
Regulatory Landscape Newsletter – October 2019
This is our Regulatory Landscape newsletter for October 2019 with our insights on the evolving market for regulatory professionals. As is typical for this time of year, we have seen an increase in new job postings for regulatory professionals across all functions over the past few weeks. Most of the demand continues to come from[…]
Top Regulatory News Stories – Week Ending September 27, 2019
Bavarian Nordic announces U.S. FDA approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine) for prevention of Smallpox and Monkeypox disease in adults. https://www.globenewswire.com/news-release/2019/09/24/1920224/0/en/Bavarian-Nordic-Announces-U-S-FDA-Approval-of-JYNNEOS-Smallpox-and-Monkeypox-Vaccine-Live-Non-replicating-for-Prevention-of-Smallpox-and-Monkeypox-Disease-in-Adults.html Novo Nordisk’s Rybelsus, an oral-semaglutide for type 2 diabetes snagged approval from the U.S. FDA, marking it as the first such treatment to be approved in pill form. https://www.biospace.com/article/novo-nordisk-snags-fda-approval-for-oral-type-2-diabetes-drug/ Johnson & Johnson’s multiple[…]
Top Regulatory News Stories – Week Ending September 20, 2019
Ardelyx, Inc. announced that the U.S. Food and Drug Administration has approved IBSRELA® (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. https://www.prnewswire.com/news-releases/ardelyx-receives-fda-approval-for-ibsrela-tenapanor-an-nhe3-sodium-transport-inhibitor-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-300917407.html Amplyx Pharmaceuticals announced that the FDA has granted Fast Track designations for both the intravenous (IV) and oral formulations of the[…]
Top Regulatory News Stories – Week Ending September 13, 2019
Five years after securing its first approval in idiopathic lung fibrosis, Boehringer Ingelheim’s drug Ofev has been cleared to slow the rate of pulmonary decline in patients with another lung scarring disease. https://endpts.com/boehringer-ingelheims-ofev-wins-fda-approval-for-use-in-scleroderma-patients/ Ridgeback Biotherapeutics announced that the Food and Drug Administration has recently granted mAb114, an experimental treatment for Ebola, Breakthrough Therapy designation. https://www.prnewswire.com/news-releases/ridgeback-biotherapeutics-lp-announces-receipt-of-breakthrough-therapy-designation-from-fda-for-mab114-300913398.html[…]
Top Regulatory News Stories – Week Ending September 6, 2019
Two decades after launching clinical trials, Kyowa Hakko Kirin finally received FDA approval for add-on Parkinson’s therapy https://endpts.com/decades-into-the-making-kyowa-hakko-kirin-wins-fda-approval-for-add-on-parkinsons-therapy/?utm Mylan won tentative US approval for generic version of Lilly’s Alimta, but it could be years before it can be sold. https://endpts.com/mylan-wins-tentative-us-approval-for-generic-version-of-lillys-alimta-but-it-could-be-years-before-its-sold/ CARsgen Therapeutics Inc. announced the FDA has granted orphan drug designation to its investigational CAR-T[…]
Regulatory Landscape Newsletter – September 2019
This is our Regulatory Landscape newsletter for September 2019 with our insights on the evolving market for regulatory professionals. For the month of August hiring in Regulatory functions continued to be strong across the board. We saw an increase in new regulatory positions in the NY/NJ area this month, while demand for regulatory professionals remains[…]
SRA Update September/October 2019
Opportunistic Outsourcing Business coach Peter Drucker was known for dispensing some sage advice that still rings true decades later: Do what you do best and outsource the rest. What comes to mind when you hear that mantra? An immediate list likely appears of all the tasks you know are not the greatest use of[…]
Top Regulatory News Stories – Week Ending August 23, 2019
AbbVie announced that the U.S. FDA has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR). https://www.prnewswire.com/news-releases/abbvie-receives-fda-approval-of-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis-300903053.html Nabriva Therapeutics announced that the FDA has approved the oral and[…]